THYMIDINE KINASE AS A CAUSATIVE FACTOR FOR TYPE 1 HERPES SIMPLEX VIRUS RESISTANCE AGAINST ACYCLOVIR

Yannie Febby Martina Lefaan, Riani Setiadhi

Abstract


ABSTRACT

Background: Herpes Simplex Virus (HSV) infection demonstrates a high prevalence in the world. Acyclovir, one of guanine synthetic analogues, is commonly used to treat infections caused by HSV. HSV resistance against acyclovir may occur, especially in immunocompromised and immunocompetent patients, as the consequence of viral mutations. Thymidine kinase (TK) is an HSV tegument protein which plays an important role in HSV-1 resistance against acyclovir. Purpose: The purpose of this article is to review the mechanisms of TK mutation that cause HSV-1 resistance against acyclovir. Review: Acyclovir involves three stages of viral thymidine kinase phosphorylation to form acyclovir triphosphate. It prevents HSV replication by acting as a competitive inhibitor of viral DNA polymerase and a chain terminator in viral DNA synthesis. Resistance is associated with viral TK mutation that is encoded by UL23 gene. Long-term use of acyclovir may promote thymidine kinase mutation in immunocompromised and immunocompetent patients via three mechanisms, namely absolute insufficiency in TK activity (TK-negative), depletion in TK synthesis, and inability in TK phosphorylation which consequently hinders the phosphorylation of acyclovir. Herpes TK gene contains a series of cytosine and guanosine, that are important for the function and the  mutation of HSV by producing incomplete or fewer enzymes as the result of nucleotide addition or elimination in homopolymer process. Conclusion: HSV-1 resistance against acyclovir is evolved from TK mutations, in the form of TK-negative, TK low-producing, and TK altered mutants, that are unable to phosphorylate TK and accordingly disrupt acyclovir phosphorylation to convert acyclovir triphosphate.

 

Keyword : Acyclovir, Herpes simplex virus, Resistance, Thymidine kinase

Full Text:

PDF

References


Jiang Y, Feng H, Lin Y, Guo X. New strategies against drug resistance to herpes simplex virus. Int J Oral Sci. 2016;8(1):1–6.

Xu X, Che Y, Li Q. HSV-1 tegument protein and the development of its genome editing technology. Virol J. 2016;13(1):1–7.

Zhang J, Liu H, Wei B. Immune response of T cells during herpes simplex. J Zhejiang Univ Sci. 2017;18(4):277–88.

Kukhanova MK, Korovina AN, Kochetkov SN. Human Herpes Simplex Virus : Life Cycle and Development of Inhibitors. Biochemistry. 2014;79(13):1635–52.

Mäki J. Herpes Simplex Virus ( HSV ) carriage in oral mucosa and HSV serostatus among pregnant finnish woman and their spouses during a six-year follow up. Finland: Turun Yliopisto University Of Turku; 2018. 4–79 p.

Roizman B, Knipe D, Whitley Richard. Herpes Simplex Virus. In: Fields Virology. 6th ed. Wolters Kluwer Health/ Lippincott Wiliams & Wilkins; 2013. p. 1823–72.

Andrei G, Snoeck R. Herpes simplex virus drug-resistance : new mutations and insights. Antimicrob agents. 2013;26(6):551–60.

Omura N, Fujii H, Yoshikawa T, Yamada S, Harada S, Inagaki T, et al. Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence. Virol J. 2017;14(1):13–7.

Van Velzen M, Van Loenen FB, Meesters RJW, De Graaf M, Remeijer L, Luider TM, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis. 2012;205(10):1539–43.

Retamal-Díaz AR, Tognarelli E, Kalergis AM, Bueno SM, A.González P. Immune Evasion by Herpes Simplex Viruses. In: Ongradi J, editor. Herpesviridae. Hungary: IntechOpen; 2016. p. 105–46.

Piret J, Boivin G. Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management. Antimicrob Agents Chemother. 2011;55(2):459–72.

Frobert E, Burrel S, Ducastelle-lepretre S, Billaud G, Ader F, Casalegno J, et al. Resistance of herpes simplex viruses to acyclovir : An update from a ten-year survey in France. Antiviral Res. 2014;111:36–41.

Xie Y, Wu L, Wang M, Cheng A, Yang Q, Wu Y, et al. Alpha-Herpesvirus Thymidine Kinase Genes Mediate Viral Virulence and Are Potential Therapeutic Targets. Front Microbiol. 2019;10(941):1–17.

Katzung G.Bertram, Masters Susan B and Trevor AJ. Antiviral Agents. In: Basic & Clinical Pharmacology. 12th ed. New York: Mc Graw Hill Lange; 2012. p. 861–90.

Acosta EP, Flexner C. Antiviral agent (nonretroviral). In: Brunton L, editor. Goodman dan Gilman’s The Pharmacological Basis Of Therapeutics. 11th ed. Ney York; 2014. p. 1593–622.

Fujii H, Kakiuchi S, Tsuji M, Nishimura H, Yoshikawa T, Yamada S, et al. Application of next-generation sequencing to detect acyclovir-resistant herpes simplex virus type 1 variants at low frequency in thymidine kinase gene of the isolates recovered from patients with hematopoietic stem cell transplantation. J Virol Methods. 2018;251:123–8.

Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E. Acyclovir resistance in herpes simplex virus type I encephalitis : a case report. J Neurovirol. 2017;23:335–7.

Van Velzen M, Van Loenen FB, Meesters RJW, De Graaf M, Remeijer L, Luider TM, et al. Latent Acyclovir-Resistant Herpes Simplex Virus Type 1 in Trigeminal Ganglia of Immunocompetent Individuals. J Infect Dis. 2012;205(10):1539–43.

Piret J, Boivin G. Resistance of Herpes Simplex Viruses to Nucleoside Analogues: Mechanisms, Prevalence, and Management. Antimicrob Agents Chemother. 2011;55(2):459–72.

Sherman E. Antiviral Drugs. In: Whalen K, Finkel R, Panavelil TA, editors. Lippincott Illustrated Reviews Pharmacology. 6th ed. Gainesville, Florida: Wolters Kluwer; 2015. p. 567–86.

Griffiths A. Slipping and Sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance. NIH Public Accessess. 2012;14(6):251–9.

Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neuroviral. 2013;19(4):328–45.

Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73(23):4433–48.

Müller EE, Magooa MP, Lewis DA. Genetic Characterization of Herpes Simplex Virus Type 2 UL23 Thymidine Kinase in Johannesburg, South Africa. J Antivirals Antiretrovir. 2013;5(4):80–4.




DOI: http://dx.doi.org/10.20527/dentino.v5i2.8954

DOI (PDF): http://dx.doi.org/10.20527/dentino.v5i2.8954.g6385

Article Metrics

Abstract view : 680 times
PDF - 458 times

Refbacks

  • There are currently no refbacks.


Contact Us:
Faculty of Dentistry
Lambung Mangkurat University
Jalan Veteran No. 128 B Banjarmasin, Indonesia

E-mail. [email protected]
Website. fkg.ulm.ac.id

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.